Biotechnology Business Assets for Sale in London, UK

- The company is selling perpetual usage rights of an AI platform that analyzes microbiome and health data to deliver personalized nutrition and wellness plans.
- Partners can deploy and white-label the platform locally, offering premium, data-driven health solutions under their own brand.
- The sale includes the proprietary core AI algorithms and source code for the microbiome-based precision diet technology.
- Partners receive the right to unlimited API access and the ability to customize and train the AI with local data, ensuring relevance and effectiveness in their market.
- The license also grants the right to localized deployment on the partner's local servers for compliance and security, and the autonomy to operate and brand the AI as their own.
- The capacity of the AI model is virtually unlimited as it is scalable to the partner's server infrastructure, and its condition is excellent, being actively maintained by us.
- The tangible assets required for the operation are minimal and fall primarily under the partner's operational responsibility, reflecting a lean, software-driven business model.
- The partner is responsible for managing the inventory of sample collection kits (optional cost of GBP 7.5 per kit), requiring only a small fulfillment/warehouse space for storage and shipping.
- We have successfully validated our technology on a global scale, processing over 50,000 microbiome samples across 15+ countries and securing strategic partnerships with major industry players.
- Our deep-tech innovation has been recognized with prestigious global awards, including the UK Tech Rocketship Award and victories in the Sanofi and Bayer accelerator programs, establishing us as a trusted leader in the personalized health sector.
- The business is driven by a seasoned leadership team, including a serial entrepreneur CEO and a CTO with 15+ years of bioinformatics expertise, ensuring clinical validity and robust architecture.
- You can establish a high-margin, end-to-end health service by integrating our software with local Next-Generation Sequencing (NGS) laboratories.
- In this model, our partner manages the complete value chain: collecting biological samples, processing them locally, and utilizing our AI to generate premium precision diet and health reports.
- These complete diagnostic packages are then sold directly to consumers, medical clinics, and hospitals, allowing the partner to capture the full market value of every test performed.
- Alternatively, you can leverage your exclusive regional rights to create a scalable B2B sublicensing ecosystem.
- Acting as a master distributor, one can sublicense the software access to other local laboratories, wellness apps, and healthcare networks within the territory.
- This allows to generate significant recurring revenue by charging own clients for API access or white-labeled portals, effectively monetizing the technology across the entire region without needing to manage every sample personally.
- The company is headquartered in London, while the promoter is currently based in the US and has provided that number for all communications.